I would agree with that on OTC stocks but in light of Biogen interest in Anavex compounds and this being a NASDAQ stock..as well as the CEO not having diluted in the past..I think it could be to do with a forthcoming partnership or probable transfer agent fatigue in answering.
Talking about statistical probabilities; how do you see the risk reward ratio here? Must be really low considering current price level, the Biogen tie up and the multiple indications...